Home Sectors Healthcare Stock Under Review: Supernus Pharmaceuticals (NASDAQ: SUPN)

Stock Under Review: Supernus Pharmaceuticals (NASDAQ: SUPN)

SHARE

Supernus Pharmaceuticals trades as part of the drug manufacturers industry and healthcare sector. The company CEO is Jack A. Khattar. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Previous Intraday Trading Performance:

The SUPN stock showed a previous change of 1.74% with an open at 31.68 and a close of 32.10. It reached an intraday high of 32.11 and a low of 31.48.

SeekingAlpha:  Stoke Therapeutics Files Proposed Terms For IPO

Liquidity:

The stock has a market cap of $1.7b with 52.4m shares outstanding, of which the float is 51.5m shares. Trading volume reached 360,593 shares compared to its average volume of 561,112 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Supernus Pharmaceuticals shares returned 4.59% and in the past 30 trading days it returned -13.10%. Over three months, it changed -17.57%. In one year it has changed -41.32% and within that year its 52-week high was 61.25 and its 52-week low was 29.65. SUPN stock is 8.26% above its 52 Week Low.

Our calculations show a 200 day moving average of 39.73 and a 50 day moving average of 34.85. Currently SUPN stock is trading -19.21% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Stoke Therapeutics Files Proposed Terms For IPO

Earnings:

The last annual fiscal EPS for the company was reported at 2.06 that ended on 31st of December 2018, which according to the previous close, that is a PE of 15.58. Based on 5 analyst estimates, the consensus EPS for the next quarter is 0.44. The TTM EPS is 2.06, which comes to a TTM PE of 15.58.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/07/2019): 0.34
4thQtr of 2018 (Reported on 02/26/2019): 0.48
3rdQtr of 2018 (Reported on 11/06/2018): 0.52
2ndQtr of 2018 (Reported on 08/07/2018): 0.57
1stQtr of 2018 (Reported on 05/08/2018): 0.49

Base on our calculations, the intrinsic value per share is 49.18, which means it is possibly undervalued and has a margin of safety of 34.73%.

Indicators to Watch:

The current calculated beta is 1.62.

SeekingAlpha:  RV Shipments: This Recession Predictor Refuses To Take A Month Off

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 24.76%, return on assets is 11.13%, profit margin is 25.49%, price-to-sales is 4.09 and price-to-book is 3.44.

Company Scores:

All scores are out of six:
 4  :Valuation Score
 3  :Past Performance Score
 5  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.